Login to Your Account



Clinic Roundup


Tuesday, May 8, 2012
• NovaDigm Therapeutics Inc., of Grand Forks, N.D., reported Phase I data showing a single dose of NDV-3, a prophylactic vaccine containing recombinant Als3, a surface adhesion/invasion from Candida albicans, was safe and well tolerated, with or without alum adjuvant, and induced strong antibody and T-cell immune responses.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription